VRAX logo
VRAX NASDAQ GB

Virax Biolabs Group Limited - Ordinary Shares

Health Care · Health Care Website · IPO Jul 2022
$0.17
▼ $-0.02 (-12.12%)
Vol 2.4M
3
Quality Score
fail
Mkt Cap
$1.5M
ROE
-102.5%
Margin
-188748.8%
D/E
10.13
Beta
1.76
52W
$0–$3

Wall Street Consensus

7 analysts · Apr 2026
2
Strong Buy
4
Buy
1
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating

Price Chart

Fundamentals Trend

Metric 2025-03-31 2025-09-02 2025-10-02 2025-11-03 2025-12-03 2026-01-02
ROE (TTM) -84.5% -84.5% -84.5% -84.5% -84.5% -102.5%
P/E (TTM)
Net Margin -239479.7% -95754.3% -95754.3% -95754.3% -95754.3% -188748.8%
Gross Margin -3376.1% -838.4% -838.4% -838.4% -838.4% -1515.0%
D/E Ratio 6.62 6.62 6.62 6.62 6.62 10.13
Current Ratio 7.27 7.27 7.27 7.27 7.27 11.35

Key Ratios

ROA (TTM)
-93.0%
P/S (TTM)
502.16
P/B
0.9
EPS (TTM)
$-1.25
52W High
$3.20
52W Low
$0.35
$0.35 52-Week Range $3.20

How does VRAX compare to Health Care peers?

Peer group: Micro-cap Health Care (All) · 241 companies

VRAX valuation vs Health Care peers

P/E ratio
0% below peers (30.7)
vs Peers
vs Industry
Undervalued
P/S ratio
502.2
19363% above peers (2.6)
vs Peers
vs Industry
Overvalued
P/B ratio
0.9
69% below peers (2.8)
vs Peers
vs Industry
Undervalued
Div yield
0% below peers (0.7%)
vs Peers
vs Industry
Low yield

VRAX profitability vs Health Care peers

ROE
-102.5%
166% below peers (-38.5%)
vs Peers
vs Industry
Weak
Net margin
-188748.8%
764375% below peers (-24.7%)
vs Peers
vs Industry
Weak
Gross margin
-1515.1%
2963% below peers (52.9%)
vs Peers
vs Industry
Weak
ROA
-93.0%
338% below peers (-21.2%)
vs Peers
vs Industry
Weak

VRAX financial health vs Health Care peers

D/E ratio
10.1
47% below peers (19.3)
vs Peers
vs Industry
Above avg
Current ratio
11.4
426% above peers (2.2)
vs Peers
vs Industry
Strong liquidity
Beta
1.8
68% above peers (1.1)
vs Peers
vs Industry
More volatile

VRAX fundamentals radar

VRAX Peer median Industry

VRAX profitability vs leverage

Bubble size = market cap · X = net margin · Y = D/E ratio

VRAX vs peers: key metrics

Latest News

No related news yet